Related Experiment Videos
Normal thymic uptake of 2-deoxy-2[F-18]fluoro-D-glucose
H Alibazoglu1, B Alibazoglu, E F Hollinger
1Department of Diagnostic Radiology and Nuclear Medicine, Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois 60612, USA.
Clinical Nuclear Medicine
|August 10, 1999
Summary
Whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) positron emission tomography (PET) identified abnormal uptake in a patient with recurrent thyroid cancer. This uptake was later determined to be normal thymus tissue, potentially visualized due to prior radioiodine therapy.
Area of Science:
- Nuclear Medicine
- Oncology
- Radiology
Background:
- Recurrent thyroid follicular cancer management often involves diagnostic imaging.
- Positron emission tomography (PET) with 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) is utilized for detecting cancer recurrence.
- Radioiodine (I-131) therapy is a standard treatment for thyroid cancer.
Observation:
- A whole-body FDG PET scan revealed significant uptake in the thyroid bed and anterior mediastinum of a patient with recurrent thyroid cancer.
- Previous I-131 scans also showed uptake in these areas.
- Post-surgical re-evaluation showed no FDG or I-131 uptake in the anterior mediastinum.
Findings:
- The mediastinal lesion initially suspected as recurrent cancer was histopathologically confirmed as normal thymus tissue.
- The visualization of the normal thymus with FDG PET may have been influenced by prior high-dose radioiodine treatment.
Implications:
- FDG PET imaging findings in the anterior mediastinum should be interpreted cautiously in patients with a history of radioiodine therapy.
- Distinguishing between recurrent thyroid cancer and normal physiological uptake (like thymus) is crucial for accurate diagnosis and treatment planning.
- Understanding the impact of prior treatments on imaging results can improve diagnostic accuracy in oncology.